ERBB2 and neoplasm: Despite being a new molecule, zanidatamab has already been used to treat different HER2+ (positive) tumor types, including locally advanced or metastatic BTC [62], extrahepatic cholangiocarcinoma, and gallbladder cancer [63], gastroesophageal adenocarcinoma [64], and advanced endometrial carcinoma and carcinosarcoma [65].